Sentynl acquires Eiger’s Zokinvy to treat rare genetic disease progeria
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 May 24
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 May 24
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Apr 24
ONO will merge Deciphera with and into its fully owned subsidiary, with Deciphera as the surviving entity, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Apr 24
Clearmind will get exclusive global rights to develop, research, manufacture, and market products derived from psychedelic compounds, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Apr 24
In the Phase 3 study, Columvi plus chemotherapy showed a statistically significant improvement in overall survival (OS), progression-free…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Mar 24
Cardior is engaged in the discovery and development of therapies that prevent, repair and reverse diseases of the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Mar 24
The transaction complements AstraZeneca’s oncology portfolio with Fusion’s pipeline of RCs, including its lead programme FPI-2265, and replaces…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Mar 24
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Mar 24
The data from FRONTIER 2, the long-term extension to Phase 2b FRONTIER 1 study, showed that JNJ-2113 resulted…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Mar 24
Acoramidis is an investigational, next-generation, orally administered, highly potent and selective small molecule transthyretin (TTR) stabiliser, intended for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates